- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06909825
FPI-2265 (225AC-PSMA-I & T) e Olaparib per pazienti con carcinoma prostatico metastatico resistente alla castrazione (MCRPC)
Uno studio di Fase 2, in aperto, multicentrico di FPI-2265 (225AC-PSMA-I & T) e Olaparib nei partecipanti con carcinoma prostatico resistente alla castrazione metastatica (MCRPC)
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I&T) in combination with Olaparib in participants with mCRPC. The study will be conducted in two parts, with Part A enrolling participants who have been previously treated with lutetium-177 (177Lu) vipivotide tetraxetan or other 177Lu-PSMA radioligand therapy (RLT) and Part B enrolling participants who have not been previously treated with lutetium-177 (177Lu) vipivotide tetraxetan or other 177Lu-PSMA radioligand therapy. For each part of the study, a Simon 2-stage design will be used to evaluate two dosing regimens. The purpose of this investigation is to determine the recommended FPI-2265 dose and regimen. Conclusions from this Phase 2 study will be based on safety, tolerability, and anti-tumor activity data. Participants with PSMA-positive mCRPC will be allocated to Arm 1 and Arm 2 in a singular, alternating fashion, until all Stage 1 participants are enrolled into each of the two regimens:
Arm 1: Will consist of up to six doses of FPI-2265 every six weeks at Dose A and olaparib twice a day on days 1 to 14 of each cycle.
Arm 2: Will consist of up to nine doses of FPI-2265 every four weeks at Dose B and olaparib twice a day on days 1 to 14 of each cycle Participants will be monitored and assessed for efficacy response, disease progression, and adverse events.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2113
- Macquarie University Hospital
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Icon Cancer Centre Kurralta Park
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Adult male participants with mCRPC that is progressing at the time of study entry
-
ECOG performance status 0-1 and life expectancy of at least three months
-
Must have received at least one novel anti-androgen deprivation therapy
-
Participants with known BRCA mutations should have received approved therapies such as PARP inhibitors, per Investigator discretion.
-
All prior treatment-related AEs must have resolved to CTCAE Grade ≤1 (except alopecia).
-
Participants must have had prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L)
-
Positive PSMA PET/CT scans .
-
Participants must have adequate organ and bone marrow function:
- Hgb >/= 9g/dL
- Platelets >/= 100 x 10^9/L
- ANC </= 1.5 x 10^9/L
- CrCL >/= 50 mL/min
Exclusion Criteria:
- Previous treatment with any of the following within 6 months of first dose: Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation.
- Participants who received more than two (2) prior lines of cytotoxic chemotherapy for CRPC.
- Participants with known unresolved urinary tract obstruction.
- Transfusion- or growth factor-dependent participants.
- Participants with a history of CNS metastases are excluded, except those who have received therapy (and are neurologically stable, asymptomatic, and not receiving corticosteroids for the purposes of maintaining neurologic integrity.
- Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
- Participants with any liver metastases.
- Participants with skeletal metastases presenting as a superscan .
- Previous history of interstitial lung disease or non-infectious pneumonitis.
- Participants with a history or clinical and/or laboratory features suggestive of MDS/AML.
- Major surgery ≤28 days prior to the first dose of study treatment.
- Planning to conceive a pregnancy during the treatment and up to six months after the last treatment.
- Participants unable to swallow orally administered medications or with malabsorptive gastrointestinal disorders.
- Concomitant use of known strong or moderate CYP3A inhibitors or inducers
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part A
Regimen 1: FPI-2265 (Dose A intravenously [IV] every six weeks) plus olaparib (twice daily [BID], on Days 1 to 14 of each cycle). Regimen 2: . FPI-2265 (Dose B intravenously [IV] every 4 weeks) plus olaparib (twice daily [BID], on Days 1 to 14 of each cycle) |
PSMA ligand radiolabeled with Ac225 Poly (ADP-ribose) polymerase (PARP) inhibitor |
|
Sperimentale: Part B
Regimen 1: FPI-2265 (Dose A intravenously [IV] every six weeks) plus olaparib (g twice daily [BID], on Days 1 to 14 of each cycle). Regimen 2: . FPI-2265 (Dose B intravenously [IV] every 4 weeks) plus olaparib (twice daily [BID], on Days 1 to 14 of each cycle) |
PSMA ligand radiolabeled with Ac225 Poly (ADP-ribose) polymerase (PARP) inhibitor |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate anti-tumour activity of FPI-2265 administered in combination with olaparib
Lasso di tempo: From first dose until approximately 12 weeks after the first administered dose of FPI-2265
|
The frequency and proportion of participants with PSA50 response will be summarized, where PSA50 is defined as ≥50% decline in PSA level from pre-treatment. |
From first dose until approximately 12 weeks after the first administered dose of FPI-2265
|
|
Evaluate the safety and tolerability of FPI-2265 administered in combination with olaparib
Lasso di tempo: From first dose until end of long-term follow-up, 5 years from the last administered dose of FPI-2265
|
Safety will be assessed by percentage of patient with treatment emergent adverse events and serious adverse events; percentage of patients with SAEs during the first year of the long term follow up and the number of AESIs during the 5 year follow up period. Percentage of patients with interruption of FPI-2265; percentage of patients who discontinue treatment; number and grade for AEs related to study treatment. |
From first dose until end of long-term follow-up, 5 years from the last administered dose of FPI-2265
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Dipti Shoop, Fusion Pharmaceuticals Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- FPI-2265-203
- CT-2024-CTN-00137-1 (Altro identificatore: TGA Clinical Trial Notification (CTN))
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .